Nicox S.A.
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutics to maintain vision and improve ocular health. The company's primary business involves creating and advancing a pipeline of investigational drugs for ophthalmological diseases. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop in development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. Nicox advances its portfolio through in-house research and strategic partnerships with other pharmaceutical companies for clinical development and commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-23 07:30 |
Earnings Release
Nicox : Résultats financiers du premier semestre 2025
|
French | 227.0 KB | ||
| 2025-10-23 07:30 |
Earnings Release
Nicox Provides First Half 2025 Financial Results
|
English | 216.7 KB | ||
| 2025-10-02 07:30 |
Earnings Release
Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois da…
|
French | 178.3 KB | ||
| 2025-10-02 07:30 |
Earnings Release
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Cli…
|
English | 167.2 KB | ||
| 2025-09-04 07:30 |
Capital/Financing Update
Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant…
|
French | 217.6 KB | ||
| 2025-09-04 07:30 |
Capital/Financing Update
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globall…
|
English | 188.1 KB | ||
| 2025-08-26 07:30 |
Regulatory News Service
Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site i…
|
French | 155.8 KB | ||
| 2025-08-26 07:30 |
Regulatory News Service
Nicox Announces Shareholder Q&A Webpage Available
|
English | 153.6 KB | ||
| 2025-08-12 15:53 |
Declaration of Voting Results & Voting Rights Announcements
Franchissement de seuils
|
French | 113.6 KB | ||
| 2025-08-08 07:30 |
Share Issue/Capital Change
Nicox Extends Existing Flexible Equity Financing
|
English | 181.9 KB | ||
| 2025-08-05 07:30 |
Regulatory News Service
Nicox annonce l’initiation par son partenaire Kowa d’un essai clinique de Phase…
|
French | 176.0 KB | ||
| 2025-08-05 07:30 |
Regulatory News Service
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
|
English | 171.5 KB | ||
| 2025-06-30 07:30 |
Earnings Release
Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Dena…
|
French | 161.2 KB | ||
| 2025-06-30 07:30 |
Regulatory News Service
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
|
English | 156.1 KB | ||
| 2025-06-06 07:30 |
Pre-Annual General Meeting Information
Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 27 ju…
|
French | 184.6 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
